China Anti-Graft Watchdog Visits Roche Amid Pharma Crackdown


John Huang of MWE China Law Offices noted that “more and more” multinational pharmaceutical firms doing business in China “have been visited by the SAIC [State Administration for Industry and Commerce] in the wake of the GSK case,” in which that agency played a lead role in bringing corruption charges against executives of Glaxosmithkline. Read the full article